Loading...
•
Mar 31, 2022
Relmada Q1 2022 Earnings Report
Reported first quarter 2022 financial results and provided a corporate update.
Key Takeaways
Relmada Therapeutics reported its first quarter 2022 financial results, highlighting the progress of its REL-1017 clinical data readouts for the Reliance Phase 3 program.
The Reliance Phase 3 program for REL-1017 is progressing as planned.
Clinical data readouts for REL-1017 are expected to begin mid-year.
Enrollment of Reliance III, the monotherapy registrational Phase 3 trial, is expected to be completed and top-line results presented by mid-year 2022.
Top-line results from Reliance I and Reliance II, the adjunctive MDD studies, are expected throughout the second half of the year.
Relmada
Relmada
Forward Guidance
Relmada anticipates completing the enrollment of Reliance III and presenting top-line results by mid-year 2022, followed by top-line results from Reliance I and Reliance II throughout the second half of the year.